Dr. Shulman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Edison Clinic
222 W. 39th Ave
San Mateo, CA 94403
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Infectious Disease, 1996 - 2000
University of ChicagoResidency, Internal Medicine, 1991 - 1995
University of Kansas School of MedicineClass of 1991
Certifications & Licensure
CA State Medical License 1995 - 2025
IL State Medical License 1991 - 1996
Clinical Trials
- Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure Start of enrollment: 2008 Sep 01
Publications & Presentations
PubMed
- 15 citationsEfficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease.Eric Lawitz, Edward Gane, Eric Cohen, John M. Vierling, Kosh Agarwal
Kidney International Reports. 2019-02-01 - 20 citationsDynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection.Jacinta A. Holmes, Charles Carlton-Smith, Arthur Y. Kim, Emily O. Dumas, Joelle Brown
Journal of Viral Hepatitis. 2019-01-03 - 2 citationsEfficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.Mario G. Pessoa, Jose Valdez Ramalho-Madruga, Katia Alves, Estevão P. Nunes, Hugo Cheinquer
Annals of Hepatology. 2018-10-16
Journal Articles
- inform \shulman, lancet
Press Mentions
Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial EnrollmentJune 3rd, 2023
Grant Support
- Feasibility Of CCR5 Inhibitors In Preventing Maternal To Infant SIV TransmissionNational Center For Research Resources2009–2010
- Feasibility Of CCR5 Inhibitors In Preventing Maternal To Infant SIV TransmissionNational Institute Of Allergy And Infectious Diseases2008–2009
- Non-Nucleoside Reverse Transcriptive HypersensitivityNational Institute Of Allergy And Infectious Diseases2002–2006
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
